Suppr超能文献

肝纤维化发病机制与诊断的新概念;一篇综述文章。

New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article.

作者信息

Ebrahimi Hedyeh, Naderian Mohammadreza, Sohrabpour Amir Ali

机构信息

Liver and Pancreaticobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Assistant Professor, Liver and Pancreaticobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Middle East J Dig Dis. 2016 Jul;8(3):166-178. doi: 10.15171/mejdd.2016.29.

Abstract

Liver fibrosis is a potentially reversible response to hepatic insults, triggered by different chronic diseases most importantly viral hepatitis, alcoholic, and nonalcoholic fatty liver disease. In the course of the chronic liver disease, hepatic fibrogenesis may develop, which is attributed to various types of cells, molecules, and pathways. Activated hepatic stellate cell (HSC), the primary source of extracellular matrix (ECM), is fundamental in pathophysiology of fibrogenesis, and thus is the most attractable target for reversing liver fibrosis. Although, liver biopsy has long been considered as the gold standard for diagnosis and staging of hepatic fibrosis, assessing progression and regression by biopsy is hampered by its limitations. We provide recent views on noninvasive approaches including serum biomarkers and radiologic techniques.

摘要

肝纤维化是对肝脏损伤的一种潜在可逆反应,由不同的慢性疾病引发,其中最重要的是病毒性肝炎、酒精性肝病和非酒精性脂肪性肝病。在慢性肝病过程中,可能会发生肝纤维化,这归因于多种类型的细胞、分子和途径。活化的肝星状细胞(HSC)是细胞外基质(ECM)的主要来源,在肝纤维化的病理生理学中起关键作用,因此是逆转肝纤维化最具吸引力的靶点。尽管长期以来肝活检一直被视为肝纤维化诊断和分期的金标准,但活检评估进展和消退存在局限性。我们提供了关于包括血清生物标志物和放射学技术在内的非侵入性方法的最新观点。

相似文献

1
New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article.
Middle East J Dig Dis. 2016 Jul;8(3):166-178. doi: 10.15171/mejdd.2016.29.
2
Non-invasive diagnosis of advanced fibrosis and cirrhosis.
World J Gastroenterol. 2014 Dec 7;20(45):16820-30. doi: 10.3748/wjg.v20.i45.16820.
3
Liver fibrosis: Direct antifibrotic agents and targeted therapies.
Matrix Biol. 2018 Aug;68-69:435-451. doi: 10.1016/j.matbio.2018.04.006. Epub 2018 Apr 12.
5
Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
World J Gastroenterol. 2020 Jan 14;26(2):109-133. doi: 10.3748/wjg.v26.i2.109.
6
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2016 Jun;150(8):1811-1822.e4. doi: 10.1053/j.gastro.2016.03.008. Epub 2016 Mar 19.
7
[Hepatic fibrogenesis].
Korean J Gastroenterol. 2006 Nov;48(5):297-305.
9
Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
PLoS One. 2020 May 22;15(5):e0233702. doi: 10.1371/journal.pone.0233702. eCollection 2020.
10
Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Clin Sci (Lond). 2017 Jun 7;131(12):1301-1315. doi: 10.1042/CS20170175. Print 2017 Jun 1.

引用本文的文献

1
Cellular and immune landscape of chronic liver diseases: insights from immunophenotyping.
Front Mol Biosci. 2025 Jan 29;11:1521811. doi: 10.3389/fmolb.2024.1521811. eCollection 2024.
4
The interaction between polyphyllin I and SQLE protein induces hepatotoxicity through SREBP-2/HMGCR/SQLE/LSS pathway.
J Pharm Anal. 2023 Jan;13(1):39-54. doi: 10.1016/j.jpha.2022.11.005. Epub 2022 Nov 19.
5
Meta-Analysis of APP Expression Modulated by SARS-CoV-2 Infection via the ACE2 Receptor.
Int J Mol Sci. 2022 Jan 21;23(3):1182. doi: 10.3390/ijms23031182.
6
Silencing of CD147 inhibits hepatic stellate cells activation related to suppressing aerobic glycolysis via hedgehog signaling.
Cytotechnology. 2021 Apr;73(2):233-242. doi: 10.1007/s10616-021-00460-9. Epub 2021 Feb 18.
7
Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of studies.
World J Gastroenterol. 2020 Dec 21;26(47):7444-7469. doi: 10.3748/wjg.v26.i47.7444.
8
Antiliver Fibrosis Screening of Active Ingredients from L. Seeds via GC-TOF-MS and UHPLC-MS/MS.
Evid Based Complement Alternat Med. 2020 Feb 18;2020:8321732. doi: 10.1155/2020/8321732. eCollection 2020.
10
The Use of Antifibrotic Recombinant nAG Protein in a Rat Liver Fibrosis Model.
Biomed Res Int. 2019 Jun 2;2019:9846919. doi: 10.1155/2019/9846919. eCollection 2019.

本文引用的文献

1
Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study.
Am J Gastroenterol. 2016 Jul;111(7):986-94. doi: 10.1038/ajg.2016.65. Epub 2016 Mar 22.
2
Transcriptomic analysis of the effects of Toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells.
Fibrogenesis Tissue Repair. 2016 Feb 18;9:2. doi: 10.1186/s13069-016-0039-z. eCollection 2016.
4
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
Dig Dis Sci. 2016 May;61(5):1282-93. doi: 10.1007/s10620-016-4054-0. Epub 2016 Feb 8.
5
Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
Medicine (Baltimore). 2016 Feb;95(5):e2630. doi: 10.1097/MD.0000000000002630.
6
A clustering based method for collagen proportional area extraction in liver biopsy images.
Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:3097-100. doi: 10.1109/EMBC.2015.7319047.
7
Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis.
Am J Physiol Cell Physiol. 2016 Mar 15;310(6):C436-45. doi: 10.1152/ajpcell.00423.2014. Epub 2015 Dec 2.
9
High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis.
PLoS One. 2015 Nov 16;10(11):e0143222. doi: 10.1371/journal.pone.0143222. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验